Anebulo Pharmaceuticals, Inc. anticipated releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. The results of the study, conducted in sixty healthy subjects challenged with delta-9-tetrahydrocannabinol, better known as THC, will be used to design the next step forward in the clinical trial for ANEB-001 as a potential treatment of ACI.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 USD | -1.08% |
|
-3.23% | -13.22% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.22% | 5.45Cr | |
+40.80% | 5.37TCr | |
+35.79% | 3.89TCr | |
-8.05% | 3.88TCr | |
-8.98% | 2.73TCr | |
+10.69% | 2.59TCr | |
-16.21% | 2.03TCr | |
+31.00% | 1.28TCr | |
+28.51% | 1.22TCr | |
-1.67% | 1.2TCr |
- Stock Market
- Equities
- ANEB Stock
- News Anebulo Pharmaceuticals, Inc.
- Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022